NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

An example of CART Cell therapy approved by FDA to treat relapsed & refractory Multiple Myeloma is

Idecabtagene Vicleucel ( Abecma)

Clinical trials with Abecma